Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 26,13 € (+69,79 %). La médiane est de 26,73 € (+73,68 %).
| Acheter |
15 |
| Conserver |
8 |
| Vendre |
0 |
Actualités Accéder au fil d'actualités
Summit Therapeutics rises after Jefferies upgrade
Summit Therapeutics' stock climbed 5.8% in pre-market trading after Jefferies upgraded the stock from “Hold” to “Buy” and raised its price target from $15 to $25. Jefferies bases the recommendation on expected H3 data on progression-free survival to be reported at the end of 2026, which analyst Faisal Khurshid believes are likely to reach statistical significance provided the transfer of data from China shows no unusual deviations. The bank sees a probable hazard ratio of 0.65–0.70 for progression-free survival and expects a possible positive effect on overall survival by mid-2027; it also views the first-in-class status of ivonescimab as value-enhancing. » Plus sur de.investing.com
Summit Therapeutics: Phase-III breakthrough - Ivonescimab outperforms Keytruda in overall survival
New analyses show that Ivonescimab achieved a statistically significant benefit in overall survival versus Keytruda in Phase-III data. Partner Akeso successfully completed the HARMONi-2 study, reinforcing the potential of the lead compound. The results reduce development risk and strengthen the chances for future approvals and the company’s global market position. » Plus sur finanzen.net
Positive phase‑III data on lung cancer push Summit Therapeutics stock up premarket
Summit Therapeutics shares rose about 4.8% premarket after partner Akeso released positive overall survival data from the Phase‑III HARMONi‑2 study of ivonescimab in non‑small cell lung cancer. The monotherapy showed a statistically significant advantage over pembrolizumab, but concrete metrics such as hazard ratio or median survival times were not disclosed. Ivonescimab is already approved and commercially available in China; in Summit’s licensed territories, including the USA and Europe, the drug is still under investigation. An analyst left the rating at neutral pending further details. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -189 M | 45,95 % |
| EBITDA | -189 M | 46,21 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 12,28 Md € |
Nombre d'actions | 797,75 M |
Plus haut/bas sur 52 semaines | 26,04 € - 10,75 € |
| Dividendes | Non |
Bêta | -1,24 |
Ratio P/E | -15,42 |
Ratio PEG | 0,33 |
Ratio P/B | 21,33 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Summit Therapeutics Inc. ist ein biopharmazeutisches Unternehmen, das Medikamente zur Behandlung von Infektionskrankheiten in den Vereinigten Staaten und Lateinamerika erforscht, entwickelt und vermarktet. Das Unternehmen führt klinische Programme durch, die sich auf Clostridioides-difficile-Infektionen (CDI) konzentrieren. Der führende Produktkandidat des Unternehmens ist Ridinilazol, ein oral verabreichtes niedermolekulares Antibiotikum, das sich in klinischen Phase-III-Studien für die Behandlung von CDI befindet. Darüber hinaus bietet das Unternehmen SMT-738 zur Bekämpfung von multiresistenten Infektionen, insbesondere von Carbapenem-resistenten Enterobacteriaceae-Infektionen, und die DDS-04-Serie zur potenziellen Behandlung von Infektionen durch Enterobacteriaceae an. Das Unternehmen wurde im Jahr 2003 gegründet und hat seinen Sitz in Cambridge, Massachusetts.
| Nom | Summit Therapeutics |
| PDG | Robert W. Duggan |
| Siège social | Miami,
fl Royaume-Uni |
| Site web | |
| Secteur | Matériaux |
| Industrie | Produits chimiques |
| Introduction en bourse | 05/03/2015 |
| Employés | 265 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
NASDAQ | SMMT |
